ST Segment Elevation Myocardial Infarction in the COVID-19 Era: Appraisal of the Evidence.

IF 1.2 Q2 MEDICINE, GENERAL & INTERNAL
Clinical Medicine & Research Pub Date : 2022-03-01 Epub Date: 2022-01-27 DOI:10.3121/cmr.2021.1707
Somto Nwaedozie, Shereif H Rezkalla
{"title":"ST Segment Elevation Myocardial Infarction in the COVID-19 Era: Appraisal of the Evidence.","authors":"Somto Nwaedozie,&nbsp;Shereif H Rezkalla","doi":"10.3121/cmr.2021.1707","DOIUrl":null,"url":null,"abstract":"<p><p>The COVID-19 pandemic continues to present a public health challenge and has had a significant impact on the presentation, time-dependent management, and clinical outcomes of ST elevation myocardial infarction (STEMI). Patients with COVID-19 and pre-disposing cardiovascular risk factors like hypertension, hyperlipidemia, and diabetes mellitus are at a higher risk of developing STEMI, and global trends have highlighted delayed management of STEMI, which may contribute to worse clinical outcomes. Prolonged time to intervention has also resulted in an increased rate of no reflow, which is an independent risk factor for worse outcomes in these patients. Timely primary percutaneous coronary intervention (PCI) remains standard of care for STEMI and can be attained within the recommended 90 minutes timeline from hospital presentation. A coordinated, safe, standardized, algorithmic approach among emergency medical services, emergency departments, and cardiac catheterization laboratory is needed to ensure optimal patient outcome during and after the COVID-19 pandemic. The focus of this case report is to highlight the challenges of PCI for ST elevation myocardial infarction in the COVID-19 era.</p>","PeriodicalId":47429,"journal":{"name":"Clinical Medicine & Research","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390854/pdf/0200052.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine & Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3121/cmr.2021.1707","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

The COVID-19 pandemic continues to present a public health challenge and has had a significant impact on the presentation, time-dependent management, and clinical outcomes of ST elevation myocardial infarction (STEMI). Patients with COVID-19 and pre-disposing cardiovascular risk factors like hypertension, hyperlipidemia, and diabetes mellitus are at a higher risk of developing STEMI, and global trends have highlighted delayed management of STEMI, which may contribute to worse clinical outcomes. Prolonged time to intervention has also resulted in an increased rate of no reflow, which is an independent risk factor for worse outcomes in these patients. Timely primary percutaneous coronary intervention (PCI) remains standard of care for STEMI and can be attained within the recommended 90 minutes timeline from hospital presentation. A coordinated, safe, standardized, algorithmic approach among emergency medical services, emergency departments, and cardiac catheterization laboratory is needed to ensure optimal patient outcome during and after the COVID-19 pandemic. The focus of this case report is to highlight the challenges of PCI for ST elevation myocardial infarction in the COVID-19 era.

Abstract Image

ST段抬高型心肌梗死在COVID-19时代的证据评价。
COVID-19大流行继续构成公共卫生挑战,并对ST段抬高型心肌梗死(STEMI)的表现、时间依赖性管理和临床结果产生重大影响。COVID-19合并高血压、高脂血症和糖尿病等心血管易感危险因素的患者发生STEMI的风险更高,全球趋势突出了STEMI的延迟管理,这可能导致更差的临床结果。干预时间的延长也导致无血流再流率的增加,这是这些患者预后较差的独立危险因素。及时的初级经皮冠状动脉介入治疗(PCI)仍然是STEMI的标准治疗,可以在医院就诊后推荐的90分钟时间内实现。在COVID-19大流行期间和之后,需要在急诊医疗服务、急诊科和心导管实验室之间采取协调、安全、标准化的算法方法,以确保患者获得最佳结果。本病例报告的重点是强调在COVID-19时代PCI治疗ST段抬高型心肌梗死的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Medicine & Research
Clinical Medicine & Research MEDICINE, GENERAL & INTERNAL-
CiteScore
1.80
自引率
7.10%
发文量
25
期刊介绍: Clinical Medicine & Research is a peer reviewed publication of original scientific medical research that is relevant to a broad audience of medical researchers and healthcare professionals. Articles are published quarterly in the following topics: -Medicine -Clinical Research -Evidence-based Medicine -Preventive Medicine -Translational Medicine -Rural Health -Case Reports -Epidemiology -Basic science -History of Medicine -The Art of Medicine -Non-Clinical Aspects of Medicine & Science
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信